Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A small molecule targeting hepatitis B surface antigen inhibits clinically relevant drug-resistant hepatitis B virus.

The Journal of antimicrobial chemotherapy - 28 Jul 2022

Kiruthika S, Bhat Ruchika, Jayaram B, Vivekanandan Perumal

Abstract excerpt

BACKGROUND: Currently approved oral antivirals for chronic HBV infection target the reverse transcriptase (RT) domain of the HBV polymerase. Emergence of drug resistance has been reported in a small proportion of chronic HBV patients on prolonged treatment with antivirals. We recently reported ZINC20451377, a small molecule targeting hepatitis B surface antigen (HBsAg) that effectively inhibits both WT HBV and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B

Share to Hepatitis B, Chronic

Share to Hepatitis B Surface Antigens

Share to Hepatitis B virus

Share to Lamivudine

Share to RNA-Directed DNA Polymerase

Source

Identifiers

PMID: 35514268
DOI: 10.1093/jac/dkac148

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A small molecule targeting hepatitis B surface antigen inhibits clinically relevant drug-resistant hepatitis B virus.PMID 35514268Read ↗

Drug resistance mutations of hepatitis B virus (HBV) influence the yield of the virions of the human hepatitis delta virus (HDV) and their infectivity.Semantic proximity Read ↗

Control of Hepatitis B Virus with Imdusiran, a Small Interfering RNA TherapeuticSemantic proximity Read ↗

Antiviral therapies: focus on hepatitis B reverse transcriptase.Semantic proximity Read ↗

Decreased infectivity of nucleoside analogs-resistant hepatitis B virus mutants.Semantic proximity Read ↗

Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sitesSemantic proximity Read ↗

Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion.Semantic proximity Read ↗

Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B.Semantic proximity Read ↗

Nucleos(t)ide analogues causes HBV S gene mutations and carcinogenesis.Semantic proximity Read ↗

Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.Semantic proximity Read ↗

First Report of Tenofovir Alafenamide Treatment Failure in Chronic Hepatitis B with Detection of Putative Tenofovir Resistance MutationsSemantic proximity Read ↗

New amino acid changes in drug resistance sites and HBsAg in hepatitis B virus genotype H.Semantic proximity Read ↗

Entecavir-resistant hepatitis B virus decreases surface antigenicity: A full genome and functional characterization.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.